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Summary: For 4 years, we determined the mode and risk of mother-to-child 
transmission of HTLV-I in a prospective cohort of 34 children born to sero- 
positive mothers in Franceville, Gabon. We also determined the prevalence of 
antibodies to HTLV-1/11 in siblings born to seropositive mothers. Antibodies to  
HTLV-1/11 were detected by Western blot, and the proviral DNA was detected 
by the polymerase chain reaction (PCR). The risk of seroconversion to anti- 
HTLV-I for the 4 years of follow-up was 17.5%. Anti-HTLV-1/11 and proviral 
DNA were only detected after age 18 months. We observed a seroprevalence 
rate of 15% among the siblings born to HTLV-1/11 seropositive mothers. Fur- 
thermore, we report a case of mother-to-child transmission of HTLV-II infec- 
tion in a population of HTLV-II-infected pregnant women that is emerging in 
Gabon. The lack of detection of HTLV-1/11 proviral DNA in cord blood and 
amniotic fluid and, furthermore, the late seroconversion observed in the chil- 
dren indirectly indicate that mother-to-child transmission occurred postnatally, 
probably through breast milk. Key Words: HTLV-Mother-to-child tran 
sion-Prospective cohort-Sibling-Familial clustering-Polymerase cha 
action-Western blot-Amniotic fluid. 
The three major routes of transmission of 
HTLV-I as yet reported include mother-to-child 
transmission, sexual intercourse, and blood prod- 
ucts (1-5). The importance of mother-to-child trans- 
mission was confirmed by a prospective cohort 
study performed in Nagasaki (6): 22% of the infants 
born to seropositive mothers were found to be 
HTLV-I carriers, and seroconversion in the infants _. , 
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was observed between the age of 1 and 3 years. 
Thereafter, several studies in Japan confirmed that 
mother-to-child transmission is mainly through 
breast-feeding (7,8), with transmission rates ranging 
from 15 to 25% (9-12). However, a case of trans- 
placental (intrauterine) transmission has been re- 
ported (13), with demonstration of HTLV-I- 
infected cells in a cord blood sample. 
However, in Africa, data on the mode and risk of 
reconversion are lacking, and data from Japan or 
other industrialized nations may not be extrapo- 
lated to be the same in Africa. For instance, 
mother-to-child transmission rates of the human im- 
munodeficiency virus range from 13 to 32% in in- 
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dustrialized countries and from 25 to 48% in devel- 
oping countries (14). 
In 1987, in Franceville, Gabon, we initiated a pro- 
spective cohort study on the mother-to-child trans- 
mission of HTLV-I. Gabon, in western equatorial 
Africa, is endemic for HTLV-I; it has a prevalence 
of 5 and 10.5%, respectively, in urban and rural 
areas (15). In Franceville, the overall HTLV-I se- 
roprevalence rate is 9.5%. Among pregnant women, 
it is estimated at 10.5% (15). In this population of 
seropositive pregnant women, we first examined 
whether mother-to-child transmission of HTLV is 
intrauterine or postpartum. Second, we determined 
the risk of mother-to-child transmission. In addi- 
tion, we determined the seroprevalence rate of 
HTLV-1/11 among siblings born to seropositive 
mothers. We used Western blot as the method of 
diagnosis, and the polymerase chain reaction (PCR) 
for detecting the proviral DNA. The PCR also al- 
lows diagnosis of infection within the follow-up pe- 
riod. 
MATERIALS AND METHODS 
Study Population 
The patient samples for this study were part of a folllow-up 
study to determine the impact of HTLV-I infection on the course 
and outcome of pregnancy (16). The studly was initiated in 1987 
at the general hospital in Franceville, southern province of Ga- 
bon, where most pregnant women in Haut-Ogoue Province are 
monitored and give birth. To optimize follow-up, only women 
living in Franceville and attending the general hospital were re- 
cruited after verbal informed consent. 
A total of 135 pregnant women wece recruited for the study; 45 
were seropositive and 90 were seronegative for HTLV-1/11 by 
Western blot. Pregnant women who were indeterminate on 
Western blot were excluded from the study. Each seropositive 
woman was matched for age and ethnic group with two seroneg- 
ative women who attended the unit for the first time on the same 
day or the day after the seropositive woman. The women se- 
lected for this study were of the lower socioeconomic class, thus 
belonging to a relatively homogeneous population. The average 
ages of the women were 25.4 years 2 5.5 for cases and 25.2 years 
f 6.2 for controls. Clinical examination of the mothers was per- 
formed by a physician once during the pregnancy, at delivery, 
and 1 year after birth for clinical manifestations of HTLV-I in- 
fection. During each bleeding of the infants, they were clinically 
examined, and information on their blood transfusion status and 
on breast-feeding was obtained. 
To shed light on the mode of transmission, in 1987, blood 
samples from the mothers and cord blood for PCR were system- 
atically taken at delivery to determine the possibility of intra- 
uterine transmission. Furthermore, amniotic fluid was obtained 
from 15 seropositive mothers to test by PCR for proviral HTLV-I 
and HTLV-II in desquamed epithelial cells. Then, every 6 
months until 1991 blood was collected from the children for 
HTLV-I serology and PCR to determine postnatal transmission. 
The incidence and risk of HTLV-I seroconversion in the first 4 
years of life were calculated. Furthermore, a complementary 
HTLV-1/11 seroprevalence survey was performed among 100 sib. 
lings, aged I to 14 years, living in the same house as the mothers. 
Detection of HTLV-1/11 Antibodies 
Sera were tested for immunoglobulin G antibodies to HTLV- 
1/11 by enzyme-linked immunosorbent assay (ELISA) (Cam- 
bridge Biotech, Worcester, MA, U.S.A.), and the ELISA posi- 
tives were retested for confirmation by Western blot (Cambridge 
Biotech). A sample was considered positive for anti-HTLV-I/II 
when it showed a band on at least two gene products (p19 or p24 
for gag antigens and gp46 for the envelope antigen) on Westem 
blot. 
Detection of HTLV-I and HTLV-II DNA by PCR in 
Blood Samples 
Peripheral blood mononuclear cells were separated by ficoll- 
hypaque density gradient centrifugation and DNA extracted es- 
sentially as previously described (17). The DNA preparation was 
then subjected to PCR according to the protocol of Saiki et al. 
(18). Samples were analyzed with two primer couples, one for 
the HTLV-I gag region (gag 1, gag 2) with the corresponding 
probe (19), the other for the pol region (SKllO, SKlI l )  (20) with 
specific probe for the HTLV-! and XTLV-II pol region (SK112, 
SK18S) (20). Samples were analyzed in duplicate and under code 
in Paris and in Antwerp. 
Detection of HTLV-I and HTLV-II by PCR in 
Amniotic Fluid 
Desquamed epithelial cells were obtained from amniotic fluid 
after centrifugation in phosphate-buffered saline. DNA was ex- 
tracted from cells by lysis with a buffer containing 20 mM Tris 
(pH 8), 5 mMEDTA (pH 8), 0.4% SDS, 149 FI H20, and 20 p&l 
proteinase K. The tube content was then vortexed (1 min) and 
incubated in a water bath at 37°C for 12 to 16 h. Then, 150 pl 
phenol/chloroform (v/v) was added and vortexed (1 min) fol- 
lowed by centrifugation (15,000 rpm) at room temperature for 5 
min. The supernatant was then decanted and 500 pI ether added 
to the pellet followed by vortexing (5 min) and centrifuging as 
noted. DNA was precipitated with 3 M ammonium acetate and 2 
vol ethanol at 4°C. After centrifugation at 15,000 rpm for 15 min 
at 4"C, the supernatant was decanted, and the pellet washed 
twice by centrifuging with SO% ethanol. The pellet was air dried 
and resuspended in H,O. The extracted DNA was then subjected 
to PCR as previously described (18). 
Statistical Analysis 
For each year after birth the number of person-years at risk 
was calculated. Seroconversions that occurred within this year 
were assumed to have occurred in the middle of the year. This 
was used to calculate the incidence over the 4 years after birth. 
The annual average incidence over the 4 years after birth was 
calculated to estimate the risk of seroconversion in the first 4 
years of life with the help of the following standird formula: risk 
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Vol. 12, No. 2 ,  1996 
smission. 
he first 4 
ementary 
g 100 sib- 
mothers. 
) HTLV- 
i) (Cam- 
SA posi- 
ambridge 
TLV-1/11 
19 or p24 
Western 
?CR in 
)y ficoll- 
icted e$- 
tion was 
iki et al. 
one for 
ponding 
20) with 
(SK112, 
ler code 
t in 
tic fluid 
was ex- 
&i Tris 
tin) and 
150 pl 
lin) fol- 
re for 5 
r added 
ging as 
e and 2 
15 min 
washed 
ir dried 
bjected 
!O pg/pI 
at risk 
is year 
r. This 
birth. 
th was 
first 4 
ia: risk 
MOTHER-TO-CHILD TRANSMISSION OF HTLV 
= I - exp(- rate x time). A confidence interval was derived 
from the estimation of the asym@totic variance of the annual 
incidence rate. 
RESULTS 
Of the 45 HTLV-1/11 Western blot positive moth- 
ers tested, 43 (95.6%) were positive for HTLV-I and 
2 (4.4%) for HTLV-II by PCR. The 43 HTLV-I pos- 
itive mothers gave birth to 44 infants, of whom 36 
(81.8%) and 23 (52.3%) were followed-up for 2 and 
4 years, respectively. The 2 HTLV-II positive 
mothers gave birth to 2 infants who were also fol- 
lowed for 4 years. 
During the first year, 2 children from HTLV-I 
positive mothers and 3 children from seronegative 
mothers died (2/36 vs. 3/69, X = 0.56 NS). Thus, 
only 34 children of HTLV-I positive mothers were 
followed for the first 2 years. No infant had a blood 
transfusion during the follow-up period. Ville et al. 
(16) did not observe any impact on fetal outcome by 
maternal HTLV-I infection in pregnancy. Children 
were lost for follow-up because of migration to 
other parts of Gabon. The minimum age of weaning 
of the infants was 8 months, and the average was 
10.1 months. No clinical manifestations of HTLV-I 
infection were found during pregnancy or 1 year 
after delivery in both mothers and children. Fur- 
thermore, no recurrent infective dermatitis or per- 
sistent lymphadenopathic syndrome in infected 
children was observed. 
Serological Follow-up by Western Blot 
All 45 samples from the cord blood of babies born 
to seropositive women, except one, showed the 
same Western blot pattern as the corresponding se- 
ropositive mother. Six months after birth, maternal 
antibodies in the children had disappeared except 
for four infants who still showed antibodies to viral 
core proteins at 9 months of age. By 12 months, all 
the children were negative in Western blot as in the 
control group, and no Western blots were indeter- 
minate (Table 1). The first antibodies to disappear 
were the anti-env (gp46), and the last were the anti- 
Overall, a seroconversion.risk of 17.5% (95% CI, 
2.4-30.2%) was observed after a 4-year follow-up 
(Table 2). The first seroconversion was observed 18 
months after birth. By the age of 2 years, a total of 
4 of the 34 children had seroconverted. By the age 
of 3 years, one more child had seroconverted, mak- 
p19. 
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TABLE 1. Prevalence of HTLV-I seropositivity on sequential 
blood samples f i om childreii born to seropositive motliers 
Western blot PCR 
Age (mo) No. tested No. pos. No. tested No. pos. 
O" 34 34 34 O 
6 34 4 21 O 
12 34 O NT 
18 34 1 NT 
24 34 4 16 26 
30 23 5 NT 
36 23 5 14 26 
42 23 5 NT 
48 23 5 NT 
PCR, polymerase chain reaction; no. pos., number positive; 
NT, not tested. 
u Thirty-four infants' cord blood samples were taken at birth 
(O). 
Two of 16, and 2 of 14 were positive on Western blot and 
PCR; the rest were negative. The samples tested by PCR at 6,24, 
and 36 months were randomly selected. 
ing a total of 5 seroconverters (Tables 1 and 2). The 
annual average incidence of seroconversion was 
4.8% during a 4-year follow-up, and the incidence 
varied after age 1 year but before age 3 years (Table 
2). But no other child seroconverted in the fourth 
year of follow-up (Tables 1 and 2). The pattern of 
appearance of antibodies was the same for all the 
children who seroconverted, with anti-p19 and anti- 
p24 appearing first and anti-gp46 later. Among the 
66 negative controls followed, no children from ini- 
tially seronegative mothers seroconverted for 
HTLV-I. 
PCR Analysis of Mother-To-Child Transmission 
Among the children born to HTLV-positive 
mothers, it is interesting that none of the cord blood 
lymphocytes (46 samples) nor the amniotic fluid (15 
samples) were positive for HTLV-I or HTLV-II, 
thus suggesting that transmission was not intrauter- 
ine or perinatal. All cord blood samples from chil- 
TABLE 2. Incidence of HTLV-I seroconversion by age among 
children born from HTLV-I seropositive mothers 
Rate per 100 
No. person No. person years 
Age years at risk seroconversions (95% CI> 
0-1 34 O O 
1-2 32.5 4 12.3 (0.2-24.4) 
2-3 20.25 1 4.9 (0.0-14.6) 
3-4 18 O O 
Total 104.75 5 : y  ' 4.8 (0.6-9.0) 
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dren bom to seronegative mothers were negative in 
PCR. 
Among the samples available for PCR analysis, 
we selected 21 samples at 6 months, 16 at 2 years, 
and 14 at 3 years after birth, while including at least 
2 Western blot positive samples at each stage of 
testing. Of these children tested, 2 of 16 were pos- 
itive by 2 years after birth and 2 of 14 more became 
positive for HTLV-I by 3 years after birth (Table 1). 
The children positive on PCR were positive on 
Western blot, while the others negative on PCR 
were negative on WB as well. All the 21 samples 
tested at age 6 months were negative, thus confirm- 
ing that these children were not infected. Further- 
more, 1 child with indeterminate Western blot pat- 
tern at age 1.5 years was negative by PCR. This 
same child was also negative on WB and on PCR at 
3 years of age. 
HTLV-1/11 Seroprevalence Among Siblings 
A total of 100 siblings, aged 1 to 14 years, born to 
seropositive mothers (group I) and 175 born to se- 
ronegative mothers (group II) were tested for anti- 
HTLV-1/11 by ELISA and Western blot. In group I, 
15 of 100 (15%) were positive versus 1 of 175 (0.6%) 
in group II (Table 3). The child positive in group II 
was multitransfused for sickle cell anemia. 
Mother-To-Child Transmission of HTLV-II 
Of the two HTLV-II PCR positive mothers' chil- 
dren consecutively followed for the 4-year study 
period, one child was confirmed by PCR and West- 
ern blot to have been infected and seroconverted; 
the other child stayed negative throughout follow-up. 
DISCUSSION 
Several modes of HTLV-I transmission from 
mother-to-child have been suggested, including in- 
trauterine, perinatal, or postnatal. Our findings of 
TABLE 3.  Seroprevalence of HTLV-IIII in siblings (aged 1 to 
14 years) born to seropositive a.nd seronegative mothers 
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No. tested No. pos. ?6 pos. 95% CI 
Group I" 100 15,. . 15 8-22 
Group II" 175 n 0.6 0-1.8 
No. pos, number positive in enzyme-linked immunosorbent 
" Groups I and II are siblings bom to seropositive and sero- 
assay (ELISA) and Westem blot. 
negative mothers, respectively. 
lack of detection of HTLV-I or -II by PCR in cord 
blood or amniotic fluid support those of Hino et al. 
(6), in a series of 227 cord blood samples from 
HTLV-I seropositive mothers, did not find any case 
of HTLV-I-containing cells or antibody activity in 
the IgM class. This suggests that intrauterine infec- 
tion is less likely to be the major route of matemal 
HTLV-I transmission. If, therefore, perinatal trans- 
mission plays a major role in maternal transmission, 
HTLV-I or II proviral DNA would have been de- 
tected ~6 months after birth, but this was not the 
case in our study (Table I). Furthermore, this pos- 
sibility of perinatal transmission may be excluded 
since IgG antibodies gradually disappeared 
year, and seroconversions were only observed at 
age > I  year. Because -20% of breast-fed infants 
compared to 3% bottle-fed infants or HTLV-I car- 
rier mothers are infected (10,21) and because all the 
cord blood samples in our study were HTLV-I/II 
negative on PCR, it is likely that the at-risk period 
during which transmission could occur would be 
during the breast-feeding period. We note that lym- 
phocytes bearing HTLV-I in breast milk from car- 
rier mothers (8,22,23) and the ora! transmission of 
HTLV-I in a monkey model (24,25) have been re- 
ported, thus suggesting postnatal transmission. Our 
results of late seroconversion and detection of 
HTLV-I by PCR after age 1 year are evidence sup- 
porting postnatal transmission. However, our sam- 
ple size may limit a firm conclusion. 
In our study, the annual average incidence of 
anti-HTLV-I antibodies in infants born to seropos- 
itive mothers with 4 years of follow-up was 4.8%, 
and the risk of seroconversion was 17.5%. No other 
child seroconverted after age 3 years. Similar to our 
findings, Kusuhara et al. (10) also observed there 
was no seroconversion in children after age 3 years 
in a 15-year follow-up study in Japan. Despite the 
diverging life-style and environmental factors in Ja- 
pan compared to Gabon, reports have indicated that 
e15 to 22% of children born to HTLV-I seroposi- 
tive mothers seroconvert by age 3 years (6,10,26). 
Fifteen percent of children born to HTLV-I sero- 
positive mothers in Jamaica seroconvert (27), re- 
sults that are similar to ours. 
The seroprevalence rate of 15% (28%) of HTLV- 
1/11 among the siblings aged 1 to 14 years is a useful 
index of this infection in a young generation of an 
HTLV-1/11 endemic population in Gabon. Seropos- 
itivity observed for HTLV-I in children and young 
adolescents is probably due to mother-to-child 
transmission (10). However, in our study, we can- 
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not confirm whether the siblings' mothers were in- 
fected before their first births. This high seroprev- 
alence rate calls for future prevention strategies and 
points to the need for an effective testing of blood 
for transfusion. 
Since the first description of HTLV-II infection 
in Gabon (28), different reports have confirmed the 
presence of this virus in other African countries 
(29-31). However, reports on the modes of trans- 
mission in these countries are lacking. To our 
knowledge, we report the first case of mother-to- 
child transmission of HTLV-II in Gabon. More in- 
vestigation on the modes of transmission of this vi- 
rus in Africa are warranted. 
We and others (32) have shown that children born 
to seropositive carrier mothers passively acquire 
maternal antibodies prenatally that decline and dis- 
appear over time. High levels of maternal anti- 
HTLV-I have been suggested to correlate with high 
levels of HTLV-I-positive lymphocytes in breast 
milk and are associated with transmission in long- 
term ( 3 6  months) breast-fed children (27,33). 
Therefore, babies of carrier mothers who are 
breast-fed for a long time (38 months in our study) 
would continue to ingest HTLV-I-infected lympho- 
cytes from the breast milk as the passively acquired 
high-titered and anti-env (anti-HTLV-I) antibodies 
gradually disappear from circulation, thus resulting 
in HTLV-I infection. We note it has recently been 
shown that maternal antibody may inhibit HTLV-I 
infection by short-term breast-feeding (3 months), 
but would not inhibit HTLV-I infection by long- 
term breast-feeding after the decay of the maternal 
antibody (32). However, this may not be applicable 
in the developing world because the advantages of 
breast-feeding outweigh the risk of HTLV-I- 
associated morbidity. Alternatively, it is conceiv- 
able that immunization of seropositive pregnant 
women, as has been demonstrated in newborn rab- 
bits (34), with high-titered anti-env antibodies might 
be an effective means of boosting passively ac- 
quired antibodies in infants to protect against 
HTLV-I infection. 
In conclusion, the lack of detection of HTLV by 
PCR in cord blood and amniotic fluid and the late 
seroconversions are arguments for postnatal trans- 
mission in which maternal milk plays an important 
role, because none of the children had blood trans- 
fusion during the follow-up period. This is the first 
report of a prospective study on mother-to-child 
transmission of HTLV-I in Africa. More studies in 
other regions of Africa are warranted. 
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